Viromed Medical AG (Viromed; ISIN: DE000A3MQR65), a medical technology company and pioneer in cold plasma technology, today provided a strategic update on its operational orientation. The Company’s focus remains on sustainable, technology-driven growth in the international MedTech market, concentrating on the development of innovative medical devices and translational research in severe respiratory diseases, particularly ventilator-associated pneumonia (VAP).
Over the past two years, Viromed has developed two novel cold plasma medical devices: ViroCAP® for medical wound healing and PulmoPlas®, a globally unique cold plasma system for applications in pneumology and respiratory tract infections. PulmoPlas® is highlighted as the next-generation technological platform with future scaling potential across multiple medical indication areas.
In research, Viromed has established a high-performance scientific consortium comprising Hannover Medical School (MHH), the Helmholtz Centre for Infection Research (HZI) in Braunschweig, and the Leibniz Institute in Jena. This network brings together expertise in infectiology, pneumology, and translational research to develop novel therapeutic approaches for respiratory tract diseases. The comprehensive publication of results by MHH and HZI is expected at the end of January 2026.
For technological development, Viromed works closely with Relyon Plasma, a subsidiary of TDK, and has established international partnerships in Europe, Korea, and Turkey to support future market entry. The Company deliberately refrains from short-term operational updates, emphasizing communication of substantial and relevant milestones aligned with long-term, sustainable corporate development.
Viromed’s corporate strategy is geared toward long-term value generation, with research and development programs consistently aligned with medical benefit, clinical relevance, and sustainable market potential. Viromed is recognized as a pioneer in pneumological research and plasma technology, and its innovation work has the potential to shape future therapeutic approaches for severe respiratory infections. According to its own assessment, Viromed will play a significant role in the global fight against pathogenic germs, particularly with PulmoPlas®.
Additionally, Viromed has successfully overcome new regulatory hurdles for the approval of ViroCAP® over the past 18 months, with market acceptance and demand already very high.
For more information, visit www.viromed-medical-ag.de or view the original release on www.newmediawire.com.
